The General Assembly Raised Bill No. 6771, effective January 1, 2026, mandates that all individual and group health insurance policies in Connecticut provide coverage for biomarker testing. Biomarkers are defined as measurable characteristics, such as gene mutations or protein expressions, that indicate biological processes or responses to treatments. Biomarker testing includes the analysis of various biospecimens, such as tissue or blood, to detect these indicators for the diagnosis, treatment, management, or monitoring of diseases or conditions.

The bill specifies that this coverage applies to policies delivered, issued for delivery, renewed, amended, or continued in the state on or after the effective date. The intent of the legislation is to ensure that patients have access to necessary biomarker testing as part of their healthcare coverage, thereby improving the management of their health conditions. The bill introduces new legal language to the existing statutes, emphasizing the importance of biomarker testing in modern medical practice.